EGRIFTA(TM) (Tesamorelin for Injection) Approved in Mexico

MONTREAL, CANADA--( Jul 14, 2015) - Theratechnologies Inc. (Theratechnologies) (TH.TO) is pleased to announce that COFEPRIS, Mexico's health agency, has approved the 2mg/vial presentation of tesamorelin for the treatment of lipodystrophy.

Theratechnologies' partner, sanofi, will re-submit a file to COFEPRIS to seek approval of the 1mg/vial presentation of EGRIFTA™ which is the one currently marketed in other territories. As was the case with Canada, the commercialization of EGRIFTA™ in Mexico will be initiated upon obtaining approval of the 1mg/vial presentation.

"We are very pleased with COFEPRIS' decision. We view Mexico as the cornerstone of Latin America for EGRIFTA™ and we are proud that EGRIFTA™ may soon be available to the Latin American population," said Luc Tanguay, President and CEO, Theratechnologies Inc.

Intellipharmaceutics Updates Status of Tentative Approvals of Generic Focalin XR(R)

TORONTO, July 8, 2015 -- Intellipharmaceutics International Inc. (IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today advised that the United States Food and Drug Administration ("FDA") has indicated to the Company that it has rescinded its previous requirement that the Company meet newly-imposed conditions for bioequivalence prior to receiving final approval for the Company's tentatively-approved strengths of its generic Focalin XR(R) (dexmethylphenidate hydrochloride extended-release) capsules (the "Product"). The strengths affected include 5 mg, 10 mg, 20 mg and 40 mg. The already-approved 15 mg and 30 mg strengths now in the market are not affected.

Oculus Innovative Sciences Receives New U.S. Patent for Microcyn(R) Technology in Treatment of Atopic Dermatitis

PETALUMA, Calif., July 8, 2015 - Oculus Innovative Sciences, Inc. (OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the receipt of a new U.S. patent for the use of the Microcyn(R) Technology hypochlorous acid in the treatment and mitigation of atopic dermatitis.

Dr. Bob Northey, Oculus senior vice president for research and development said: "Our intellectual property portfolio is perfectly synced with our new focus on the dermatology market with our direct sales force. The empirical evidence demonstrating Microcyn's efficacy in the treatment of atopic dermatitis is highly compelling. This new patent provides Oculus market exclusivity for the use of hypochlorous acid with broad ranges of activity in the treatment of atopic dermatitis until the year 2027 when the patent expires."

Horizon Pharma plc Proposes to Acquire Depomed, Inc. for $29.25 per Share in an All-Stock Transaction, Representing a 42 Percent Premium to Depomed's Shareholders

DUBLIN, IRELAND--(Jul 7, 2015) - Horizon Pharma plc (NASDAQ: HZNP)

• Transaction would generate significant revenue and operating synergies, tax savings and would also be immediately and substantially accretive to Horizon's adjusted diluted earnings per share
   
• Projected full-year pro forma combined 2015 net sales and adjusted EBITDA would be in excess of $950 million and $350 million, respectively, based on Depomed's and Horizon's existing guidance
  

  Published: 07 July 2015

  Written by Editor

  Nasdaq   M & A   Up on News  

  Read more: Depomed Inc ( DEPO )